Chikungunya Fever Market Research Report – Global Forecast till 2027

Chikungunya Fever Market Research Report: By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests), Treatment (Allopathy, Homeopathy), End User (Hospitals And Clinics, Academic Institutes, Research Laboratories) - Global Forecast till 2027

ID: MRFR/Pharma/3273-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Chikungunya is a mosquito borne viral disease caused by the RNA virus belonging to the alphavirus genus of family Togaviridae. Chikungunya fever has been reported in more than 60 countries of Asia, Africa, Europe and the Americas. Its transmission from human to human is facilitated by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. Currently, there is no cure for the disease and the treatments are focussed only to relieve the symptoms. In 2019, according to the World Health Organisation, 349 936 suspected and 146 914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported the most cases were Brazil (265 000 suspected cases), Bolivia and Colombia (19 000 suspected cases, respectively).


Increasing per capita healthcare expenditures, rising R&D investments by the market players, and growing geriatric population are the major factors that will drive the market growth during the forecasted period. Moreover, pouring government investments and favourable policies will fuel the market. However, factors such as lack of awareness and cost of treatment and diagnosis can restrain the market growth during the forecasted period.


The chikungunya fever market is expected to grow at CAGR 6.10% during forecast period. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1:- Chikungunya Fever Market Share, by Region Chikungunya Fever Market

Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The chikungunya fever market is segmented on the basis of diagnosis, treatment, and end-users.


On the basis of diagnosis, the market is segmented into ELISA based assays, serological tests, virological tests, and others. ELISA based assays is future segmented into IgM based ELISA and IgG ELISA.


On the basis of treatment, the market is segmented into allopathy, homeopathy, Ayurveda, and others. The allopathy segmented is sub segmented into anti-pyretics, optimal analgesics, and others. The homeopathy segment is sub segmented into pyroginum, rhus-tox, cedron, and others. The ayurveda segment is sub segmented into amrutharista, mahasudarshana churna, dhanvantaram gutika and others.


On the basis of end users, the market is segmented into hospitals and clinics, academic institutes, research laboratories, and others.


Regional Analysis


The Americas dominate the chikungunya fever market owing to a well-developed healthcare sector. Apart from this, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in the Americas. Additionally, increasing geriatric population, rising awareness among the people and expanding R&D expenses for the treatment of chikungunya is boosting the market growth. 


Europe holds the second largest market for chikungunya fever, which is followed by Asia Pacific. Availability of funds for research, rising patient population and government support for research & development will drive the market. On 22 September 2019, according to the European Centre for Disease Prevention and Control there were about 102 autochthonous chikungunya cases in Italy. Such trends for chikungunya fever was seen across the region. This is expected to boost the market growth during the forecasted period.


According to the World Health Organisation, the major outbreaks of chikungunya fever are seen in Asia and the Indian subcontinent. This made Asia Pacific the fastest growing region for the market due to the presence of a huge patient population and presence of huge opportunity in the market. Moreover, continuously developing economies like India and China within the region have increasing healthcare expenditures which fuels the market growth.


On the other hand, the Middle East & Africa has the least share in the chikungunya market due to the presence of poor economy especially in the African region. A majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 

Research Methodology


 Chikungunya Fever Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for chikungunya fever market


The key players for the chikungunya market are Quest Diagnostics Incorporated. (U.S.A), Alere. (U.S.A), Genome Diagnostics Pvt. Ltd. (India), altona Diagnostics (Europe), Bio-Rad Laboratories, Inc. (U.S.A), Sanat Products Ltd. (India), Taj Pharmaceuticals Limited. (India), and Etubics Corporation (U.S.A).



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant value
  CAGR   6.10 %(2020–2027)
  Base Year   2017
  Forecast Period   2027
  Historical Data   2016
  Forecast Units    Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Diagnosis, Treatment, End User
  Geographies Covered    North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Quest Diagnostics Incorporated. (U.S.A), Alere. (U.S.A), Genome Diagnostics Pvt. Ltd. (India), altona Diagnostics (Europe), Bio-Rad Laboratories, Inc. (U.S.A), Sanat Products Ltd. (India), Taj Pharmaceuticals Limited. (India), and Etubics Corporation (U.S.A).
  Key Market Opportunities   Lack of awareness and cost of treatment and diagnosis can restrain the market growth
  Key Market Drivers

  • Increasing per capita healthcare expenditures
  • Rising R&D investments by the market players
  • Growing geriatric population


  • Frequently Asked Questions (FAQ) :


    Chikungunya fever market is projected to grow at a 5.86% CAGR between 2017- 2023.

    The Americas is expected to dominate the chikungunya fever market.

    Favorable government policies and rising R&D investments are the key factors driving the chikungunya fever market.

    Ayurveda, homeopathy, allopathy, and others are the different treatments for chikungunya fever.

    Notable players profiled in the chikungunya fever market include Etubics Corporation (U.S.A), Taj Pharmaceuticals Limited. (India), Sanat Products Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.A), Altona Diagnostics (Europe), Genome Diagnostics Pvt. Ltd. (India), Alere. (U.S.A), and Quest Diagnostics Incorporated. (U.S.A).